93 related articles for article (PubMed ID: 9305668)
1. Therapy of hepatitis C: overview.
Lindsay KL
Hepatology; 1997 Sep; 26(3 Suppl 1):71S-77S. PubMed ID: 9305668
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.
Seya T; Takeda Y; Takashima K; Yoshida S; Azuma M; Matsumoto M
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(3):153-160. PubMed ID: 29526974
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus: Promising discoveries and new treatments.
Bastos JC; Padilla MA; Caserta LC; Miotto N; Vigani AG; Arns CW
World J Gastroenterol; 2016 Jul; 22(28):6393-401. PubMed ID: 27605875
[TBL] [Abstract][Full Text] [Related]
4. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Miotto N; Mendes LC; Zanaga LP; Goncales ES; Lazarini MS; Pedro MN; Goncales FL; Stucchi RS; Vigani AG
Braz J Med Biol Res; 2016 Jun; 49(7):. PubMed ID: 27356107
[TBL] [Abstract][Full Text] [Related]
5. Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
McNutt MD; Liu S; Manatunga A; Royster EB; Raison CL; Woolwine BJ; Demetrashvili MF; Miller AH; Musselman DL
Neuropsychopharmacology; 2012 May; 37(6):1444-54. PubMed ID: 22353759
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatitis C cryoglobulinemia: mission and challenges.
Kayali Z; Labrecque DR; Schmidt WN
Curr Treat Options Gastroenterol; 2006; 9(6):497-507. PubMed ID: 17081483
[TBL] [Abstract][Full Text] [Related]
7. Is interferon-beta an alternative treatment for chronic hepatitis C?
Moreno-Otero R; Trapero-Marugán M; Gómez-Domínguez E; García-Buey L; Moreno-Monteagudo JA
World J Gastroenterol; 2006 May; 12(17):2730-6. PubMed ID: 16718760
[TBL] [Abstract][Full Text] [Related]
8. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
9. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.
Desombere I; Van Vlierberghe H; Couvent S; Clinckspoor F; Leroux-Roels G
J Clin Microbiol; 2005 Jun; 43(6):2590-7. PubMed ID: 15956369
[TBL] [Abstract][Full Text] [Related]
10. High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study.
Yu ML; Dai CY; Chen SC; Lee LP; Hsieh MY; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
BMC Infect Dis; 2005 Apr; 5():27. PubMed ID: 15823212
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hepatitis C virus IRES-mediated translation by small RNAs analogous to stem-loop structures of the 5'-untranslated region.
Ray PS; Das S
Nucleic Acids Res; 2004; 32(5):1678-87. PubMed ID: 15020704
[TBL] [Abstract][Full Text] [Related]
12. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication.
Wang C; Pflugheber J; Sumpter R; Sodora DL; Hui D; Sen GC; Gale M
J Virol; 2003 Apr; 77(7):3898-912. PubMed ID: 12634350
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C in nonresponders to previous therapy.
Dantzler TE; Lawitz EJ
Curr Gastroenterol Rep; 2003 Feb; 5(1):78-85. PubMed ID: 12530952
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.
Kaser A; Novick D; Rubinstein M; Siegmund B; Enrich B; Koch RO; Vogel W; Kim SH; Dinarello CA; Tilg H
Clin Exp Immunol; 2002 Aug; 129(2):332-8. PubMed ID: 12165091
[TBL] [Abstract][Full Text] [Related]
15. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.
Takimoto M; Ohkoshi S; Ichida T; Takeda Y; Nomoto M; Asakura H; Naito A; Mori S; Hata K; Igarashi K; Hara H; Ohta H; Soga K; Watanabe T; Kamimura T
Dig Dis Sci; 2002 Jan; 47(1):170-6. PubMed ID: 11837720
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
17. Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy.
Wietzkebetaraun P; Meier V; Braun F; Ramadori G
World J Gastroenterol; 2001 Apr; 7(2):222-7. PubMed ID: 11819764
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
Perry CM; Jarvis B
Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of persistent TT virus infection, as determined in patients treated with alpha interferon for concomitant hepatitis C virus infection.
Maggi F; Pistello M; Vatteroni M; Presciuttini S; Marchi S; Isola P; Fornai C; Fagnani S; Andreoli E; Antonelli G; Bendinelli M
J Virol; 2001 Dec; 75(24):11999-2004. PubMed ID: 11711590
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
